Literature DB >> 26461084

Shifting the Evolving CAR T Cell Platform into Higher Gear.

Daniel R Holohan1, James C Lee1, Jeffrey A Bluestone2.   

Abstract

In this issue of Cancer Cell, Zhao and colleagues test various chimeric antigen receptor (CAR) T cells to show that CD28-CD3ζ CAR T cells that constitutively express 4-1BBL promote T cell expansion and tumor eradication while reducing exhaustion. The results have important implications for the development of effective CAR T cell therapies in cancer patients.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26461084     DOI: 10.1016/j.ccell.2015.09.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  6 in total

1.  Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer.

Authors:  R Zhang; X Zhang; B Ma; B Xiao; F Huang; P Huang; C Ying; T Liu; Y Wang
Journal:  Cancer Gene Ther       Date:  2016-04-15       Impact factor: 5.987

Review 2.  Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.

Authors:  Erhao Zhang; Jieyi Gu; Hanmei Xu
Journal:  Mol Cancer       Date:  2018-01-12       Impact factor: 27.401

Review 3.  Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.

Authors:  Zhenguang Wang; Yelei Guo; Weidong Han
Journal:  Protein Cell       Date:  2017-05-02       Impact factor: 14.870

Review 4.  Genetically enhanced T lymphocytes and the intensive care unit.

Authors:  Tiberiu Tat; Huming Li; Catalin-Sorin Constantinescu; Anca Onaciu; Sergiu Chira; Ciprian Osan; Sergiu Pasca; Bobe Petrushev; Vlad Moisoiu; Wilhelm-Thomas Micu; Cristian Berce; Sebastian Tranca; Delia Dima; Ioana Berindan-Neagoe; Jianliang Shen; Ciprian Tomuleasa; Liren Qian
Journal:  Oncotarget       Date:  2018-03-27

Review 5.  Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Authors:  Ciprian Tomuleasa; Shigeo Fuji; Cristian Berce; Anca Onaciu; Sergiu Chira; Bobe Petrushev; Wilhelm-Thomas Micu; Vlad Moisoiu; Ciprian Osan; Catalin Constantinescu; Sergiu Pasca; Ancuta Jurj; Laura Pop; Ioana Berindan-Neagoe; Delia Dima; Shigehisa Kitano
Journal:  Front Immunol       Date:  2018-02-19       Impact factor: 7.561

6.  S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity.

Authors:  Jinhua Zhang; Kun Song; Jun Wang; Yanan Li; Shuangqing Liu; Chengliang Dai; Lieping Chen; Shengdian Wang; Zhihai Qin
Journal:  Oncoimmunology       Date:  2018-01-23       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.